Effect of the mGlu2/3 orthosteric agonist LY-404,039 on abnormal involuntary movements and parkinsonism in the 6-OHDA-lesioned rat
Objective: To assess the effect of LY-404,039 on dyskinesia and parkinsonism in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson’s disease (PD). Background: LY-404,039 is an…Analysis of Sleep Structure and EEG Characteristics of Patients with Dyskinesia in Parkinson’s Disease
Objective: We aim to use objective polysomnography to analyze the relationship between dyskinesia and sleep structure in patients with Parkinson's disease. Background: Levodopa is an…Indirect Treatment Comparison of Adjunctive Treatments for Patients with Parkinson’s Disease Experiencing Motor Complications
Objective: Evaluate the comparative efficacy of treatment options for Parkinson's disease (PD) motor complications using indirect treatment comparison. Background: Amantadine delayed release/extended release (DR/ER) capsules…Belly Dancer’s Dyskinesia with Systemic Lupus Erythematosus: A Case Report
Objective: To present a rare case of belly dancer’s dyskinesia with systemic lupus erythematosus (SLE). Background: Belly dancer’s dyskinesia is a rare disease caused by…Post-infectious Anti-GFAP-associated meningoencephalitis: A case report
Objective: To report a clinical manifestation of severe choreoballistic movement in a patient with anti-glial fibrillary acidic protein (GFAP) antibody positive autoimmune encephalitis Background: GFAP…Effect of simultaneous mGlu2 positive allosteric modulation and orthosteric stimulation combined with 5-HT2A antagonism on psychosis-like behaviours, dyskinesia and parkinsonism in the MPTP-lesioned marmoset
Objective: To assess the effects of concurrent metabotropic glutamate type 2 (mGlu2) positive allosteric modulation and orthosteric stimulation combined with serotonin type 2A (5-HT2A) antagonism.…Qualitative Interviews With Children/Adolescents With Dyskinetic Cerebral Palsy (DCP) and Their Caregivers
Objective: To capture input from children/adolescents with DCP and their caregivers on the content validity of the Movement Disorders–Childhood Rating Scale (MD-CRS). Background: DCP is…Proof-of-concept study testing bevantolol (SOM3355) as treatment of chorea in Huntington’s disease
Objective: Proof-of-concept phase IIa study assessing bevantolol (SOM3355) efficacy and safety in reducing chorea in Huntington’s disease (HD). Background: Bevantolol hydrochloride, a β1‐adrenoceptor antagonist used…Analysis of Amantadine formulations for OFF and Dyskinesia in Parkinson Disease
Objective: Evaluate the effects of amantadine formulations on the treatment of OFF and dyskinesia in Parkinson’s patients. Background: There are currently three formulations of amantadine…Dyskinesia, Pain, and Quality of Life in Parkinson’s Disease: Post Hoc Analysis From the DYSCOVER Study
Objective: Evaluate correlations between dyskinesia, health-related quality of life (HRQoL), activities of daily living (ADL), and pain in patients with advanced Parkinson’s disease (PD) who…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 44
- Next Page »